Current Role of Functional Imaging in the Management of Lymphoma.

Curr Oncol Rep

LYSA Imaging, Henri Mondor University Hospitals, University Paris Est, Créteil, France.

Published: November 2021

Purpose Of Review: Functional imaging with 18FDG-PET-CT has transformed the staging and response assessment of patients with Hodgkin (HL) and non-Hodgkin lymphoma (NHL). Herein, we review the current role and future directions for functional imaging in the management of patients with lymphoma.

Recent Findings: Because of its increased sensitivity, PET-CT is the preferred modality for staging of FDG-avid lymphomas. It appears to have a role for interim assessment in patients with HL with adaptive strategies that reduce toxicity in lower risk patients and increase efficacy in those at high risk. Such a role has yet to be demonstrated in other histologies. FDG-PET-CT is also the gold standard for response assessment posttreatment. Newer uses include assessment of total metabolic tumor volume and radiomics in pretreatment prognosis. Whereas PET-CT is more sensitive than other current modalities for staging and response assessment, the future of PET-CT will be in conjunction with other modalities, notably assessment of minimal residual disease and microenvironmental markers to develop risk adaptive strategies to improve the outcome of patients with lymphoma.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-021-01127-6DOI Listing

Publication Analysis

Top Keywords

functional imaging
12
response assessment
12
current role
8
imaging management
8
staging response
8
assessment patients
8
adaptive strategies
8
assessment
6
patients
5
role functional
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!